Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dermatological adverse events with taxane chemotherapy.
Sibaud V, Lebœuf NR, Roche H, Belum VR, Gladieff L, Deslandres M, Montastruc M, Eche A, Vigarios E, Dalenc F, Lacouture ME. Sibaud V, et al. Among authors: deslandres m. Eur J Dermatol. 2016 Oct 1;26(5):427-443. doi: 10.1684/ejd.2016.2833. Eur J Dermatol. 2016. PMID: 27550571 Free PMC article. Review.
Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancer.
Betrian S, Angeles MA, Gil Moreno A, Cabarrou B, Deslandres M, Ferron G, Mery E, Floquet A, Guyon F, Pérez-Benavente A, Spagnolo E, Rychlik A, Gladieff L, Hernández Gutiérrez A, Martinez A. Betrian S, et al. Among authors: deslandres m. Int J Gynecol Cancer. 2022 Jul 20:ijgc-2021-003313. doi: 10.1136/ijgc-2021-003313. Online ahead of print. Int J Gynecol Cancer. 2022. PMID: 35858711
18F-FDG PET/CT Identifies Predictors of Survival in Patients with Locally Advanced Cervical Carcinoma and Paraaortic Lymph Node Involvement to Allow Intensification of Treatment.
Leray H, Gabiache E, Courbon F, Brenot-Rossi I, Colineaux H, Lepage B, Lambaudie E, Martinez A, Voglimacci M, Weyl A, Deslandres M, Ducassou A, Motton S, Vaysse C, Chantalat E. Leray H, et al. Among authors: deslandres m. J Nucl Med. 2020 Oct;61(10):1442-1447. doi: 10.2967/jnumed.119.238824. Epub 2020 Feb 7. J Nucl Med. 2020. PMID: 32034109 Free article.
A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer.
Bennouna J, Deslandres M, Senellart H, de Labareyre C, Ruiz-Soto R, Wixon C, Botbyl J, Suttle AB, Delord JP. Bennouna J, et al. Among authors: deslandres m. Invest New Drugs. 2015 Feb;33(1):138-47. doi: 10.1007/s10637-014-0142-1. Epub 2014 Sep 24. Invest New Drugs. 2015. PMID: 25248752 Clinical Trial.
Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma-randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol.
Modesto A, Tougeron D, Tremolières P, Ronchin P, Jouve AD, Leignel DA, Vendrely V, Riou O, Martin-Babau J, Le Sourd S, Mirabel X, Leroy T, Huguet F, Montaigne L, Baumgaertner I, Deslandres M, Moyal E, Seva C, Selves J, Otal P, Pezzella V, Guimbaud R, Filleron T, Quéro L. Modesto A, et al. Among authors: deslandres m. BMC Cancer. 2023 Oct 12;23(1):966. doi: 10.1186/s12885-023-11227-0. BMC Cancer. 2023. PMID: 37828434 Free PMC article.
15 results